Poxel SA
Research Poxel SA (POXEL) on Bullrun: market cap EUR 14.65M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPOXEL
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 14.65M
- Financial periodFY2024
- RevenueEUR 6.64M
- Revenue growth235.0%
- Net income-EUR 18.31M
- Gross margin55.7%
Valuation Snapshot
latest market cap is EUR 14.65M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | EUR 6.64M | -EUR 18.31M | n/a | 55.7% | -0.38 | EUR 3.66M | n/a | -EUR 58.93M |
| FY2023 | EUR 1.98M | -EUR 35.09M | -EUR 13.98M | 0.1% | -1.05 | EUR 2.34M | EUR 47.03M | -EUR 49.08M |
| FY2022 | EUR 674.00K | -EUR 31.40M | -EUR 21.84M | 0.3% | -1.08 | EUR 13.06M | EUR 43.44M | -EUR 18.24M |
| FY2021 | EUR 13.40M | -EUR 23.76M | -EUR 16.94M | 99.6% | -0.83 | EUR 32.29M | EUR 35.14M | EUR 8.21M |
| FY2020 | EUR 6.81M | -EUR 31.83M | -EUR 25.98M | 100.0% | -1.16 | EUR 40.20M | n/a | EUR 27.07M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 14.65M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Poxel SA's market cap?
Poxel SA's market capitalization is EUR 14.65M.
What does Poxel SA do?
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan.